Invasive markers identified by gene expression profiling in pancreatic cancer

Pancreatology

Volumn 12, Issue 2, 2012, Pages 130-140

  Rogers, A ^a   Smith, M J ^a   Doolan, P ^b   Clarke, C ^b   Clynes, M ^b   Murphy, J F ^a   McDermott, A ^a   Swan, N ^a   Crotty, P ^a   Ridgway, P F ^a   Conlon, K C ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Cancer; Carcinoma; Cell line; Gene expression microarray analysis; Human; Immunohistochemistry; Pancreas; Pancreatic ductal; PCR; Urokinase plasminogen activator receptors

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERSTITIAL COLLAGENASE; OLIGONUCLEOTIDE; PHORBOL 13 ACETATE 12 MYRISTATE; RNA; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER CELL ASPC 1; CANCER CELL BXPC 3; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CELL LINE; CELL STIMULATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MARKER GENE; MICROARRAY ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR LOCALIZATION;

EID: 84862802240     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2011.12.011     Document Type: Article

References (52)

1. Singh SM, Longmire Jr WP, Reber HA. Surgical palliation for pancreatic cancer. The ucla experience. Ann Surg 1990;212:132-9. (Pubitemid 20241036)
2. Kloppel G, Adsay NV. Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med 2009;133:382-7.
3. Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumour size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996;223:147-53. (Pubitemid 26065207)
4. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57 [discussion 257-260].
5. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. the European Study Group for Pancreatic C: a randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. (Pubitemid 38339364)
6. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77. (Pubitemid 46143304)
7. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-26. (Pubitemid 351347058)
8. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009;16:1751-6.
9. Berlin J, Hoffman JP, Regine WF. Editorial: combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus conference. Ann Surg Oncol 2009;16:1757-9.
10. Bai J, Sata N, Nagai H. Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford) 2007;9:150-5. (Pubitemid 46672391)
11. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
12. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
13. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-8. (Pubitemid 351264384)
14. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumour tissue of origin. J Clin Oncol 2009;27:2503-8.
15. Dumur CI, Lyons-Weiler M, Sciulli C, Garrett CT, Schrijver I, Holley TK, et al. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn 2008;10:67-77. (Pubitemid 351184837)
16. Longo R, Cacciamani F, Naso G, Gasparini G. Pancreatic cancer: from molecular signature to target therapy. Crc Cr Rev Oncol-Hem 2008;68:197-211.
17. Han SY, Lee MS, Kim HR, Baek SH, Ahn DH, Chae HS, et al. Phorbol 12- myristate 13-acetate induces alteration in mucin gene expression and biological properties of colon cancer cells. Int J Oncol 2000;17:487-94.
18. Park MJ, Park IC, Hur JH, Rhee CH, Choe TB, Yi DH, et al. Protein kinase c activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in d54 human glioblastoma cells. Neurosci Lett 2000;290:201-4.
19. Kast C, Wang M, Whiteway M. The erk/mapk pathway regulates the activity of the human tissue factor pathway inhibitor-2 promoter. J Biol Chem 2003;278: 6787-94. (Pubitemid 36800667)
20. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, et al. Epigenetic inactivation of tfpi-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005;24:850-8. (Pubitemid 40216093)
21. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The rin: an rna integrity number for assigning integrity values to rna measurements. BMC Mol Biol 2006;7:3.
22. Wu Z, Irizarry RA. Preprocessing of oligonucleotide array data. Nat Biotechnol 2004;22:656-8. author reply 658.
23. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (miame)-toward standards for microarray data. Nat Genet 2001;29:365-71. (Pubitemid 34326681)
24. Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, et al. Ncbi geo: mining millions of expression profilesedatabase and tools. Nucleic Acids Res 2005;33:D562-6. (Pubitemid 40207937)
25. Beissbarth T, Speed TP. Gostat: find statistically overrepresented gene ontologies within a group of genes. Bioinformatics 2004;20:1464-5. (Pubitemid 38931420)
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
27. Yuan JS, Reed A, Chen F, Stewart Jr CN. Statistical analysis of real-time pcr data. BMC Bioinform 2006;7:85.
28. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, et al. Source: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucl Acids Res 2003;31:219-23. (Pubitemid 36150369)
29. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 2000;95:17-31. (Pubitemid 30041530)
30. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009;6:e1000046.
31. Cao J, Sato H, Takino T, Seiki M. The c-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase a activation. J Biol Chem 1995;270:801-5.
32. Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008;36:160-7.
33. Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, et al. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol 2005;20:256-63. (Pubitemid 40343278)
34. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997;75:388-95. (Pubitemid 27051054)
35. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive nf-kappab activation in pancreatic cancer cells. J Biol Chem 2004;279:16452-62. (Pubitemid 38509343)
36. Ranganathan AC, Nelson KK, Rodriguez AM, Kim KH, Tower GB, Rutter JL, et al. Manganese superoxide dismutase signals matrix metalloproteinase expression via h2o2-dependent erk1/2 activation. J Biol Chem 2001;276:14264-70.
37. Saito S, Yamaji N, Yasunaga K, Saito T, Matsumoto S, Katoh M, et al. The fibronectin extra domain a activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism. J Biol Chem 1999;274:30756-63.
38. Wang X, Bi Z, Chu W, Wan Y. Il-1 receptor antagonist attenuates map kinase/ ap-1 activation and MMP-1 expression in uva-irradiated human fibroblasts induced by culture medium from uvb-irradiated human skin keratinocytes. Int J Mol Med 2005;16:1117-24.
39. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine il-1 alpha loop. J Immunol 2000;164:6174-9. (Pubitemid 30408794)
40. Aho U, Zhao X, Lohr M, Andersson R. Molecular mechanisms of pancreatic cancer and potential targets of treatment. Scand J Gastroenterol 2007;42: 279-96.
41. Takino T, Saeki H, Miyamori H, Kudo T, Sato H. Inhibition of membrane-type 1 matrix metalloproteinase at cell-matrix adhesions. Cancer Res 2007;67: 11621-9.
42. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 2007;13:2614-20. (Pubitemid 46788027)
43. Toruner GA, Ulger C, Alkan M, Galante AT, Rinaggio J, Wilk R, et al. Association between gene expression profile and tumour invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 2004;154:27-35. (Pubitemid 39286169)
44. Bao W, Fu HJ, Jia LT, Zhang Y, Li W, Jin BQ, et al. Her2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys 2010;499:49-55.
45. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24. (Pubitemid 41112921)
46. Cao D, Hustinx SR, Sui G, Bala P, Sato N, Martin S, et al. Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther 2004;3: 1081-9 [discussion 1090-1081]. (Pubitemid 41350988)
47. Hustinx SR, Cao D, Maitra A, Sato N, Martin ST, Sudhir D, et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 2004;3:1254-61. (Pubitemid 41350962)
48. Van Heek NT, Maitra A, Koopmann J, Fedarko N, Jain A, Rahman A, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther 2004;3:651-6. (Pubitemid 41351104)
49. Streit S, Michalski CW, Erkan M, Friess H, Kleeff J. Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative rt-pcr. Pancreatology 2009;9:577-82.
50. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35. (Pubitemid 30132189)
51. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009;6:412-22.
52. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase ii trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-9.